Cream formulation impact on topical administration of engineered colloidal nanoparticles by B. Santini et al.
RESEARCH ARTICLE
Cream Formulation Impact on Topical
Administration of Engineered Colloidal
Nanoparticles
Benedetta Santini1☯, Ivan Zanoni1,2,6☯, Roberta Marzi1, Clara Cigni1, Marzia Bedoni3,
Furio Gramatica3, Luca Palugan4, Fabio Corsi5, Francesca Granucci1,6, Miriam Colombo1*
1 NanoBioLab, Dipartimento di Biotecnologie e Bioscienze, Università degli Studi di Milano-Bicocca, Milano,
Italy, 2 Division of Gastroenterology, Boston Children's Hospital, Harvard Medical School, Boston,
Massachusetts, United States of America, 3 Laboratorio di Nanomedicina e Biofotonica Clinica, Fondazione
Don Carlo Gnocchi ONLUS, Milano, Italy, 4 Dipartimento di Scienze Farmaceutiche, Università degli Studi di
Milano, Milano, Italy, 5 Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”, Università degli Studi di
Milano, Milano, Italy, 6 Unit of Cell Signalling and Innate Immunity, Humanitas Clinical and Research Center,
Rozzano, Milan, Italy
☯ These authors contributed equally to this work.
* miriam.colombo@unimib.it
Abstract
In order to minimize the impact of systemic toxicity of drugs in the treatment of local acute
and chronic inflammatory reactions, the achievement of reliable and efficient delivery of
therapeutics in/through the skin is highly recommended. While the use of nanoparticles is
now an established practice for drug intravenous targeted delivery, their transdermal pene-
tration is still poorly understood and this important administration route remains almost un-
explored. In the present study, we have synthesized magnetic (iron oxide) nanoparticles
(MNP) coated with an amphiphilic polymer, developed a water-in-oil emulsion formulation
for their topical administration and compared the skin penetration routes with the same
nanoparticles deposited as a colloidal suspension. Transmission and scanning electron mi-
croscopies provided ultrastructural evidence that the amphiphilic nanoparticles (PMNP)
cream formulation allowed the efficient penetration through all the skin layers with a control-
lable kinetics compared to suspension formulation. In addition to the preferential follicular
pathway, also the intracellular and intercellular routes were involved. PMNP that crossed all
skin layers were quantified by inductively coupled plasma mass spectrometry. The obtained
data suggests that combining PMNP amphiphilic character with cream formulation im-
proves the intradermal penetration of nanoparticles. While PMNP administration in living
mice via aqueous suspension resulted in preferential nanoparticle capture by phagocytes
and migration to draining lymph nodes, cream formulation favored uptake by all the ana-
lyzed dermis cell types, including hematopoietic and non-hematopoietic. Unlike aqueous
suspension, cream formulation also favored the maintenance of nanoparticles in the dermal
architecture avoiding their dispersion and migration to draining lymph nodes via afferent
lymphatics.
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Introduction
Nanomaterials, which size is included within 1–100 nm range, hold tremendous potential in
biomedical applications thanks to the favorable combination of unique chemical and physical
size-dependent properties [1,2]. In particular, nanoparticles can be designed in many different
fashions and their clinical applications in drug delivery and diagnosis of human diseases are
taken into consideration [3]. Among them, magnetite nanoparticles are ideal candidates as
contrast agents for magnetic resonance imaging and magnetic force-assisted drug delivery sys-
tems [4]. It has been demonstrated several times that MNP are nontoxic at therapeutic dosages
and the first MNP-based medical tools have already entered the marketplace [5] or are current-
ly subjected to clinical trials [6].
Drug delivery nanosystems are meant to improve the biopharmaceutical properties of exist-
ing drugs that often exhibit a limited effectiveness in therapy. Such limitations include solid-
and suspension-state instability, poor solubility and poor drug absorption that could lead to
low bioavailability and insufficient targeting efficiency that could lead to unfavorable ratio be-
tween the amount of the administered drug and the concentration at the target tissue [7–9]. In
order to optimize the loco-regional release of therapeutics, the topical route has been one of the
most promising noninvasive delivery options, ameliorating patient compliance, improving the
pharmacokinetics of degradable compounds and reducing frequently occurring side effects
[10–12]. Nevertheless, drug topical administration remains a challenge in pharmaceutics be-
cause of the difficulties to adjust the skin penetration and to determine and reproduce the exact
amount of drug reaching the skin layers at the desired depth [13,14]. In fact, the conventional
transdermal drug delivery methods are limited by skin barrier properties according to the
“brick and mortar model” (stratum corneum) that prevents excessive water loss and offers an
efficient protective tissue against exogenous chemical, physical and mechanical stimuli and
pathogens [15].
In this scenario, the preparation of high quality engineered colloidal nanoparticles loaded
with drugs and modified with targeting molecules to improve the localized therapeutic effect
represents a promising new strategy to develop a novel generation of therapeutic agents [16].
Despite at the moment only few studies have been reported on transdermal penetration of col-
loidal nanoparticles, cutaneous administration is expected to raise interest in the next future to
achieve more efficient loco-regional delivery [17–19]. However, most attempts have mainly ex-
ploited invasive and expensive enhancement techniques or electrical methods to improve the
penetration of nanoparticles in the healthy skin, with controversial conclusions [20]. So far,
very few examples have been reported using human skin as a model for ultrastructural investi-
gations [17].
To our knowledge, cream formulations have never been exploited to improve the absorption
of nanoparticles. Water-in-oil (w/o) creams, which consist of small droplets of water dispersed
in a continuous oily phase, can be used to improve the cutaneous absorption of pharmaceutical
agents and to facilitate their penetration through the skin layers [21].
In the present work, we have synthesized MNP coated with a pro-functional amphiphilic
polymer and used them as a colloidal aqueous suspension or formulated in a w/o cream. These
nanoparticles, termed PMNP, were found to be colloidally stable both in aqueous fluids and in
a w/o cream formulation and thus particularly appropriate to gain information on the destiny
of nanoparticles. PMNP were used to study penetration in human skin samples by ultrastruc-
tural analysis and to assess nanoparticle distribution in immune cells of dermis in living mice.
Despite mice skin is remarkably thinner than human, localized cells of innate immunity behave
very similarly for this reason living mice represent a good model in order to investigate the in-
teraction between colloidal nanoparticles and dermal cytotypes.
Cream Formulation for Nanoparticles Topical Administration
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Materials and Methods
Ethics Statement
We declare that all in vivo experiments were performed using protocols approved by the Uni-
versity of Milano-Bicocca Animal Care and Use Committee. Protocols were approved by the
Italian Ministry of Health under the protocol number 11–2012. Consensus of the Ethical Com-
mittee “Niguarda Cà Granda”Hospital, Milan was obtained for the use of fresh human skin
samples.
Mice and Reagents
All mice were bred on a C57BL/6 background and animals were housed under pathogen-free
conditions. C57BL/6 mice were purchased from Charles River and were maintained in our ani-
mal facility at the University of Milano-Bicocca. Mice were housed in containment facilities of
the animal facility and maintained on a regular 12:12 hour light:dark cycle with food and water
ad libitum.
Fresh human skin samples were obtained by Bank Tissue after ethical committee consensus
(Ethical Committee “Niguarda Cà Granda”Hospital, Milan). Cell culture medium and chemi-
cals were purchased from EuroClone (Pero, Italy). All the antibodies (anti-CD11c, anti-
CD11b, anti-CD19, anti-CD3, anti-CD45.2) used for fluorescence-activated cell sorting
(FACS) analysis were purchased from BD Biosciences (San Diego, CA). For TEM images of the
tissues, at the end of Franz Cell experiment, small portions of skin were fixed in 2.5% glutaral-
dehyde in 0.1 M phosphate buffer, pH 7.2 (Electron Microscopy Sciences, Hatfield, PA), for
2 h. After one rinse with phosphate buffer, specimens were post fixed in 1.5% osmium tetroxide
(Electron Microscopy Sciences) for 2 h, dehydrated by 50, 70, 90, and 100% EtOH, and embed-
ded in epoxy resin (PolyBed 812 Polysciences Inc., Warrington, PA).
Synthesis of PMNP and cream and suspension formulation. MNP were synthesized by
solvothermal decomposition in octadecene from iron oleate precursor, as described previously
[22]. MNP (10 mg) suspended in chloroform (5 mg mL–1) were transferred to water phase by
mixing with a 0.5 M solution of an amphiphilic polymer (poly(isobutylene-alt-1-tetradecene-
maleic anhydride)) (PMA, 136 μL) in 5 mL of sodium borate buffer (SBB, pH 12) [23]. The re-
sulting PMA-coated nanoparticles (PMNP) were dispersible in aqueous media. For in vivo ex-
periments green dye-labeled PMNP were synthesized using 5(6)-carboxyfluorescein diacetate
N-succinimidyl ester (CFSE). After activation of the carboxylate groups of the PMA by 0.1 M
EDC (6.5 μL), 0.05 M 2,2-(ethylenedioxy)-bis(ethylamine) (EDBE, 2.5 μL) was added and stir-
red 2 h. Next, nanoparticle dispersion was concentrated and washed twice with water. Subse-
quently, CFSE (1.8 mg dissolved in 180 μL of dimethyl sulfoxide) was added to 8 mg of
nanoparticles, stirred 2 h and washed twice with water. The amount of CSFE onto PMNP was
determined by measuring fluorescence emission at 518 nm (λex 491 nm).
For PMNP suspension, PMNP as synthesized are concentrated in Amicon tubes (50 kDa fil-
ter cutoff) (Millipore Corporation, Billerica, MA) by centrifuging at 3000 rpm in order to ob-
tain the final concentration of 8 mg mL–1 (5 × 1014 nanoparticles mL–1). The PMNP cream
formulation was obtained by addition of 8 mg PMNP or PMNP-CFSE to 1 g of w/o cream
(Essex cream, Shering-Plough) according to the method of progressive dilution.
Dynamic light scattering (DLS) and zeta-potential measurements. DLS measurements
were performed at 90° with a 90Plus Particle Size Analyzer from Brookhaven Instruments Cor-
poration (Holtsville, NY), working at 15 mW of a solid-state laser (λ 661 nm). Nanoparticles
were dispersed in the solvent and sonicated in a S15H Elmasonic apparatus (Elma, Singen, Ger-
many) before analysis. Final sample concentration used for measurements was 5 mg mL–1.
Cream Formulation for Nanoparticles Topical Administration
PLOS ONE | DOI:10.1371/journal.pone.0126366 May 11, 2015 3 / 14
Zeta-potential measurements were elaborated on the same instrument equipped with AQ-809
electrode and data were processed by ZetaPlus Software (Brookhaven Instruments Corpora-
tion, Holtsville, NY).
Transmission electron microscopy (TEM) of MNP and PMNP. For TEM analysis, MNP
and PMNP were dispersed in hexane and water, respectively (50 μ g mL–1), and a drop of the
resulting solution was placed on a Formvar/carbon-coated copper grid and air-dried. TEM
images were obtained by a Zeiss EM-109 microscope (Oberkhochen, Germany) operating at
80 kV.
Skin preparation. A central punch biopsy of full skin thickness (epidermis, dermis and
partially hypodermis) for each specimen was reduced for Franz Diffusion Cell (FDC) analysis.
After the reduction the specimens (n = 2, for each 4 experiments) were placed in Petri dishes,
epidermis side-up and dermis submerged in PBS (0.1 M, pH 7.4), then were thawed at room
temperature (RT) till the experimental set up.
Histological analysis. A fragment of each skin biopsy was fixed in 4% buffered formalde-
hyde solution (0.1 M PBS, pH 7.4) for 5 h at RT, thoroughly washed with PBS, dehydrated
using graded ethanol, and embedded in paraffin. Paraffin serial sections were prepared at a
thickness of 5 μm, deparaffinized, and stained with haematoxylin and eosin. All sections were
analyzed using a Leica microscope (DM2500) equipped with a digital camera (Leica, Wetzlar,
Germany).
Skin penetration study with Franz Diffusion Cell. FDCs were maintained at 32°C with
thermostated water in the jacket surrounding the cells. Receptor chambers were filled with 5
mL PBS and stirred continuously using a magnetic stir bar. Human skin (epidermis side-up,
facing the donor chamber) was mounted into FDC interface and the PMNP formulations (sat-
urated NP cream>10 mg cm–2 or solution>100 μ L cm–2, volume 1 mL) were applied to the
donor chambers on the basis of an infinite dose test. All the experimental conditions were stud-
ied to simulate the physiological condition of temperature, pH and moisture. At specific time
intervals (1-3-5-7-24 h), 500 μ L samples were withdrawn from the receptor chamber using a
syringe and the same amount of fresh PBS was replaced in the same chamber at each time
point. Statistical analysis was performed by means of two-tail t-student's test (Excel 2007,
Microsoft, Redmond, WA), and the differences were considered statistically significant for
p< 0.05.
Nanoparticles quantification by ICP analysis. For ICP-OES analysis, to 500 μ L samples,
collected at specific times from the receptor chambers, were added 3 mL of aqua regia and,
after 72 h, the samples were diluted with 7 mL of distilled water. All samples were measured in
triplicate with Optima 7000 DV ICP-OES (Perkin Elmer, Waltham, MA).
Skin fixation protocol for SEM and TEM analysis. After the fixation, longitudinal skin
sections of 70–80 nm thicknesses were obtained by perpendicular cutting to avoid the tissue
disruption and were examined by means of a transmission electron microscope (Zeiss EM109)
(Zeiss, Oberkochen, Germany) operating at 80 kV. For SEM images of the tissues, at the end of
Franz Cell experiment, small portions of skin were fixed in 2.5% glutaraldehyde in 0.1 M phos-
phate buffer pH 7.2 (Electron Microscopy Sciences, Hatfield, PA), for 24 h. After one rinse
with phosphate buffer, specimens were dehydrated by 10, 25, 50, 75, and 100% EtOH, and
dried with hexamethyldisilazane. The samples are carefully mounted on a stub and coated with
a very thin film of Agar Auto Sputter Coater (Assing, Monterotondo, Italy) before SEM exami-
nation with Leica S420 Microscope operating at 15 Kv.
Isolation of skin cells. Cells were isolated as previously described [24]. Briefly, skin was
isolated and digested for 45 min in a cocktail containing collagenase XI, hyaluronidase and
DNase. 10% fetal bovine serum (FBS) was added to stop the reaction and cells were then
stained to assess the percentage of different cell populations.
Cream Formulation for Nanoparticles Topical Administration
PLOS ONE | DOI:10.1371/journal.pone.0126366 May 11, 2015 4 / 14
Flow Cytometry. Single cell suspensions were washed with ice-cold PBS and stained with
the appropriate antibody for 30 min on ice, followed by ice-cold PBS washing. Staining was as-
sessed with a FACS Calibur (Becton Dickinson).
Results and Discussion
Colloidal nanoparticles synthesis and characterization of and
formulation in a w/o cream
Hydrophobic magnetite nanoparticles (MNP) were synthesized from organometallic precur-
sors by solvothermal decomposition in octadecene [22]. The high temperature and the pres-
ence of stabilizing surfactants provided an optimal crystal nucleation and growth resulting in
highly uniform and monodisperse nanoparticles with 12.0 ± 1.2 nm average diameter, as mea-
sured by TEM, that were suspended in chloroform by virtue of the oleate surfactant coating. A
TEM image of MNPs is shown in Fig 1A. This feature was further confirmed by dynamic light
scattering (DLS) analysis, which resulted in a hydrodynamic diameter of 19.0 ± 1.3 nm in hex-
ane. To produce a stable suspension in a physiological environment, a water phase transfer of
nanoparticles was needed. To this aim, MNP were coated with an amphiphilic polymer
(PMA), obtained by reacting poly(isobutylene-alt-1-tetradecene-maleic anhydride) with an
amount of dodecylamine sufficient to react with 75% of anhydride groups (Fig 1B) [24]. In
MNP coating process, the hydrophobic alkyl chains intercalated between those of oleic acid,
which acted as a surfactant (PMNP, 12.2 ± 1.8 nm, TEMmeasured diameter). The resulting
nanoparticle suspension exhibited important advantages including: 1) a stable colloidal disper-
sion both in aqueous solution and physiological buffer; 2) the polymer coating can be easily
functionalized with drugs or targeting molecules for future therapeutic applications; 3) the am-
phiphilic coating was expected to improve the nanoparticle penetration through both hydro-
phobic and hydrophilic skin layers; 4) the amphipathic character of the composite nanomaterial
was suitable to obtain a homogenous cream nanoformulation. In this way, we developed a nano-
particle scaffold that could be formulated both in suspension (even at a PMNP concentration
of 8 mg mL–1) and in w/o cream, which might be useful for topical application. As expected,
PMNP nanoparticles coated with PMA appeared a bit larger than MNP by themselves at DLS
analysis (23.2 ± 2.0 nm) but were still stable and monodisperse in size. Beyond, the z-potential
analysis showed a strongly negative surface charge in water (z = –55.98 ± 3.18 mV). To evaluate
the potential of PMNP for future application as magnetic resonance imaging contrast enhanc-
ers, the value of decreasing concentrations of PMNP in water was 186 mM–1s–1 at 0.47 T. This
value is higher than the negative contrast power of agents currently available in approved clini-
cal diagnostic practice (r2 of Ferumxytol is 83 mM
–1s–1 at 0.47 T). For in vivo studies, CFSE was
conjugated to PMNP using the bifunctional diamino-linker 2,2-(ethylenedioxy)-bis(ethylamine)
(EDBE) previously activated by N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide (EDC).
Both labeled and unlabeled PMNP were formulated in a cream, using the method of progressive
dilution, in order to obtain a homogeneous preparation (Fig 1C). The maximum amount of
PMNP included in 1 g of cream for biological experiments was 8 mg, used to test in vitro diffu-
sion and in vivo absorption. Physical stability of the cream containing PMNP was also evaluated
in order to test the stability of the final product. The organoleptic properties did not show any
changes over two years examination.
Investigation of nanoparticle penetration through the human skin.
In order to investigate nanoparticles penetration applied with both types of formulations,
through all skin layers, in vitro skin permeation studies were carried out using normal human
Cream Formulation for Nanoparticles Topical Administration
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Fig 1. Fe3O4 nanoparticles (MNP, a) synthesized in organic solvent and transferred to a water solution using PMA amphiphilic polymer (PMNP, b).
MNP and PMNPwere highly monodisperse in size as it is shown by TEM images (scale bars = 40 nm,). Part of the highly concentrated PMNP suspension
(8 mg mL–1) was incorporated in a w/o cream (0.8 wt % concentration) (c).
doi:10.1371/journal.pone.0126366.g001
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skin in FDCs. Before the penetration study, a histological analysis was performed in parallel on
human skin biopsies to verify the morphological integrity of all skin layers. Histological exami-
nation of haematoxylin and eosin-stained skin sections revealed a regular histological appear-
ance of epidermis and dermis (Fig 2A). A deep monolayer of well-preserved cubical and
cylindrical cells (basal layer), an intermediate spinous layer, an upper granular layer, and outer-
most stratum corneum were always observed. Compact papillary and reticular dermis filled
with blood vessels were also maintained.
After histological validation, nanoparticle permeation in different skin layers was analyzed by
TEM and SEM. Receptor chambers were filled with PBS (5 mL) and PMNP were applied to the
donor chambers. Samples of receptor fluid were taken at various time intervals (1-3-5-7-24 h)
and the relevant PMNP concentrations in the receptor fluid were assessed measuring ICP-OES
values normalized with values obtained by control samples. Next, nanoparticle permeation in
different skin layers was analyzed by transmission and scanning electron microscopies. Fig 2B, at
the end of skin exposure time (24 h), shows no significant difference between cream and suspen-
sion administration was observed in the amount of diffused nanoparticles through the human
intact skin (p>0.05); on the other hand, at previous sampling times (3, 5 and 7 h), the differences
were significant (p = 3.610–9 at 3 h, p = 4.010–8 at 5 h, p = 1,810–6 at 7 h oppure p = 3.610–9,
p = 4.010–8 and p = 1,810–6 respectively). This result can be explained by the physico-chemical
properties of PMNP nanoparticles, which allowed the penetration from side to side of the skin
barrier. In fact, the superficial amphiphile-like behavior of the polymer might favor the optimal
permeation of both the hydrophobic and hydrophilic layers. The application of PMNP w/o
cream formulation gave an accelerated and homogeneous nanoparticle permeation resulting in a
reduction of the penetration and diffusion time, probably allowed by skin hydration and
achieved by cream application. Moreover, the occlusive effect of the cream prevented the water
evaporation and the loss of moisture promoting the nanoparticles penetration. Indeed, PMNP
suspension required 24 h to equilibrate the penetration kinetics through the dermis.
Electron microscopy analysis of skin penetration
There is evidence that the major constrain for skin penetration is due to the stratum corneum
barrier [12]. Three possible permeation routes have been identified including intracellular, in-
tercellular, and follicular pathways. In principle, the latter should be considered the easiest way
to occur for large molecules, due to the obvious preferential pathway along the follicular chan-
nels. However, in human skin, hair distribution represents only a small skin area fraction [14].
On the other hand, it is more difficult to discriminate between intracellular and intercellular
routes. Fig 3 shows PMNP intradermal delivery across the intact skin layers observed by elec-
tron microscopy. Nanoparticles can be clearly distinguished in all skin layers, from the surface
to deeper levels, both in cream and suspension formulations. No significant differences were
detected between the two formulations in terms of permeation mechanism and amount of pen-
etrated nanoparticles after 24 h. PMNP amphiphilic polymer coating confers nanoparticles
both a hydrophobic character, useful for the penetration of waterproof corneocyte-based stra-
tum corneum, and a hydrophilic propensity required for deeper viable epidermis permeation.
TEM images suggest that nanoparticles penetrated mainly through intercellular pathway, as
numerous nanoparticles can be distinguished across epidermis cells and through the whole
skin thickness (Fig 3A–3C). However, the presence of PMNP among corneocytes provided di-
rect evidence that the intracellular penetration pathway also occurred both in cream and in sus-
pension (TEM images in Fig 3D and 3E). PMNP were also observed close to the basal
membrane (Fig 3F). After epidermis penetration, nanoparticles reached the dermis layer,
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Fig 2. Histological microphotograph of normal human skin section. Haematoxylin and eosin staining
(original magnification 40×) (a). In vitro diffusion studies of PMNP colloidal suspension or cream in human
skin were carried out using Franz diffusion cells and diffused PMNP were quantified by ICP-OES analysis (b).
doi:10.1371/journal.pone.0126366.g002
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where they were detected in proximity to the collagen fibers (Fig 3G–3I). A large number of
nanoparticles could be recovered in the dermis in higher concentration than expected from
previous reports, probably due to the contribution of the amphiphilic polymer coating [20].
Another important observation was that, analyzing several dermis sections by TEM/SEM,
nanoparticles maintained their individuality and did not aggregate. This result was confirmed
by DLS analysis of the solution collected in the receptor chamber of the FDC, in which
Fig 3. Images of skin samples treated with PMNPcream or suspension obtained with transmission and scanning electronmicroscopy. Selected
micrographs show (a) SEM image of transversal skin section treated with PMNP solution for 24 h, SC = stratum corneum, K = keratinocytes, BM = basal
membrane, C = collagen, (b) high magnification of Fig “a”, PMNP are detected on the surface of the keratinocytes (white arrows). TEM images of PMNP
nanoparticles (black arrows) inside the corneocytes of the skin treated with cream (c, d) or suspension (e, f) PMNP nanoparticles in proximity of the basal
membrane, D = desmosomes. g), h) and i) photomicrographs of PMNP nanoparticles (black arrows) intercalated between the collagen fibers of the dermis, g)
SEM image h) and i) TEM images.
doi:10.1371/journal.pone.0126366.g003
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nanoparticles in the 35–65 nm size range were recovered. This is consistent with the assump-
tion that after passing through different skin layers, the biological identity of nanoparticles, in-
cluding the formation of a thick protein corona, was expected to change by adsorbing various
biological materials on their surface [7,24]. As control, we found the similar values measuring
PMNP size after incubating them in fetal bovine serum media.
Interaction with skin-localized cells of innate immunity in living mice
Nanoparticles incorporation by cutaneous cells was evaluated in mouse models. Cream formu-
lations of CFSE-conjugated PMNP were applied to the skin of previously shaved C57BL/6
mice (1 cm2). Mice were sacrificed 24 h later and treated skin was recovered and analyzed by
flow cytometry after having obtained single cell suspensions. Draining lymph nodes were also
analyzed to evaluate the possible transport of nanoparticle via the lymph. Skin cells of hemato-
poietic and non-hematopoietic origin were identified as CD45-positive and negative, respec-
tively. As shown in Fig 4, both populations contained fluorescent cells, indicating that both
groups of cells could incorporate PMNP nanoparticles. Since no positive staining could be ob-
served in the draining lymph nodes (Fig 4A) interestingly, nanoparticles administered with
cream formulations remained confined to the skin. It is known that sub-cutaneously (sc) inoc-
ulated substances reach the draining lymph nodes by entering the afferent lymphatics free or
associated with dendritic cells [25]. In order to double check the detection of nanoparticle-pos-
itive cells in the lymph nodes, if present, we injected CFSE-conjugated PMNP sc in an aqueous
suspension. As Fig 4A clearly shows, after sc administration, CFSE-positive cells could be clear-
ly detected in the draining lymph nodes. Since macrophages and dendritic cells are the cells
that preferentially uptake particulate antigens inside the lymph nodes, we also analyzed these
two cell types in mice that treated with PMNP cream or PMNP in aqueous solution. In the
draining lymph nodes of mice that received PMNP nanoparticle via sc administration CFSE-
positive macrophages and dendritic cells could be detected starting from 2 h after treatment.
On the other hand no positive cells could be detected in the lymph nodes of mice treated with
PMNP cream (Fig 4B). This data suggests that cream formulations, thanks to the high lipidic
concentration, permeabilize different cell types, including T and B-cells, macrophages, dendrit-
ic cells and mast cells, and non-hematopoietic cells (CD45-negative cells), and entrap the nano-
particles avoiding their dispersions. Otherwise, not being entrapped in a lipidic film,
nanoparticles freely administered in aqueous suspensions have easy open access to the afferent
lymphatics and to draining lymph nodes (Fig 5). These results indicate that cream formulations
represent the ideal solution when a topical localized treatment is needed and different cell
types have to be targeted.
Conclusions
In summary, in the present work we developed colloidal nanoparticles composed of an iron
oxide nanocrystal core coated by a tightly bound amphiphilic polymer, formulated in a w/o
cream able to permeate and penetrate the human skin. The same nanoparticles were also used
for biological experiments in colloidal suspension as control. In vitro permeation analysis, car-
ried out through intact human skin using Franz Diffusion Cell exhibited an increased, faster
and more regular penetration of nanoparticles when formulated in cream in comparison to
nanoparticle deposition as aqueous suspension. This makes nano-cream very promising for ap-
plication in local therapies. However, probably due to the amphiphilic character of the polymer
coating, nanoparticles formulated in suspension exhibited an intrinsic enhanced propensity to
penetrate through the different human skin layers as well as results reported in previous litera-
ture [26]. In vivo treatment of living mice with these nanoparticles showed their uptake by the
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Fig 4. Cytofluorimetric analysis showing PMNP nanoparticles uptake bymouse skin and lymph node
cells. PMNP suspension (a, upper panels). Skin CD45-positive and negative cells showing CFSE
incorporation. Note that most of the skin cells uptake PMNP nanoparticles administered with the cream
formulation. (a, lower panels) CFSE-positive cells in the lymph nodes of mice that received PMNP
nanoparticles via cream formulation or via sc administration. Note that only with sc PMNP administration,
nanoparticle-positive cells can be detected in the draining lymph nodes. (b) Lymph node macrophages and
dendritic cells, identified as CD11b- and CD11c-positive cells respectively, showing CFSE incorporation.
Note that only when PMNP are administered sc, CFSE positive macrophages and dendritic cells can be
detected in the lymph nodes.
doi:10.1371/journal.pone.0126366.g004
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dermal resident immune cells. In particular, when administered in the form of nano-cream
suspension, nanoparticles remained confined within the thin skin layers of mice, as no migra-
tion to the draining lymph nodes could be observed. The results obtained in this study offer
promise in the development of nano-cream for the rapid targeting of bioactive agents and
drugs in the skin barriers. Such molecules could be encapsulated in the hydrophobic shell or
covalently linked to the nanoparticle surface, supporting the topical route as a convenient alter-
native to the parenteral administration of anti-inflammatory and cytotoxic nanoconjugate
drugs reducing systemic effect of toxic agents.
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